In a Phase IIb trial of 320 adults with obesity and biopsy-confirmed MASH and fibrosis stages F1F3, subcutaneous semaglutide (0.1 mg, 0.2 mg or 0.4 mg daily for 72 weeks) resulted in a significantly higher proportion of participants with MASH resolution without worsening of fibrosis than placebo (40%, 36% and 59% in participants treated with 0.1 mg, 0.2 mg or 0.4 mg daily, respectively, compared with 17% in the placebo group)
Farmacia del Ahorro : Features a Monedero del Ahorro (Savings Wallet) program, which functions as their loyalty/discount program
You can read the abstract of this article at Before After At the age of 60, I look and feel better than I ever have in my entire life
Other side effects can include vomiting, headache, and dizziness
[Published online July 9, 2025] European Medicines Agency